Syntex/Greenwich Pharmaceuticals
Executive Summary
Syntex will develop Greenwich's Therafectin (amiprilose hydrochloride), which is currently in clinical trials for the treatment of rheumatoid arthritis. Syntex and Greenwich will hold co-exclusive rights to manufacture and market the drug in the U.S., while Syntex will hold exclusive marketing rights in Canada, Mexico, the Bahamas, Australia, New Zealand and Brazil. In addition to making royalty payments, Syntex will fund the remaining clinical trials.